The Chemotherapy Foundation

CHEMOTHERAPY FOUNDATION SYMPOSIUM XXVI
Tuesday, November 4 - Saturday, November 8
Marriott Marquis Hotel
New York City, USA

TUESDAY, NOVEMBER 4 • PEDIATRIC ONCOLOGY
Chair: Gustavo Del Toro, MD

1:30pm		EASING OF SUFFERING IN CHILDREN WITH ADVANCED CANCER
		Joanne Wolfe, MD
1:45		HEMATOPOIETIC CELL TRANSPLANTATION IN AML
		Elizabeth Roman, MD
2:00		UNRELATED UMBILICAL CORD BLOOD TRANSPLANTATION
		Vinod K. Prasad, MD
2:15		JMML: DIAGNOSTIC AND TREATMENT CONSIDERATIONS
		Todd M. Cooper, DO
2:30		NEW TRENDS IN PEDIATRIC HODGKIN'S LYMPHOMA
		Richard A. Drachtman, MD
2:45		PEDIATRIC NON-HODGKIN'S LYMPHOMA
		Stan C. Goldman, MD
3:00		Coffee Time
3:15		CURRENT CLINICAL TRIAL FOR RHABDOMYOSARCOMA
		Douglas Hawkins, MD
3:30		LIMB-SPARING SURGERY FOR BONE SARCOMAS
		James Wittig, MD
3:45		CHEMOTHERAPY FOR CHILDHOOD MALIGNANT BRAIN TUMORS
		James Garvin, MD
4:00		SIMULTANEOUS INTERRUPTION OF METABOLIC PATHWAYS IN CHILDHOOD ALL
		Julio C. Barredo, MD
4:15		ADVANCES IN TREATMENT STRATEGIES IN PEDIATRIC ALL
		Stephen Sallan, MD
4:30		Discussion
7 -9 pm		DINNER AND SPECIAL PRESENTATION
		MEETING THE CLINICAL TRIAL CHALLENGES EMERGING FROM NOVEL BIOLOGICAL PLATFORMS
		Robet J. Arceci, MD, PhD
		PROGRESS IN CHILDHOOD ACUTE LYMPHOBLASTIC LEUKEMIA
		Paul Gaynon, MD

		Election Results Live

		WEDNESDAY, NOVEMBER 5
7:00am		BREAKFAST WITH THE PROFESSORS
		AN UPDATE OF ESAs IN ONCOLOGY
		Jeffrey Crawford, MD
		CHEMOTHERAPY INDUCED THROMBOCYTOPENIA: NEW DEVELOPMENTS IN PATHOPHYSIOLOGY AND TREATMENT
		James B. Bussel, MD
8:00		WELCOME
		Steven Burakoff, MD, Janice L. Gabrilove, MD, Edward P. Ambinder, MD
		MORNING SESSION
		HEMATOLOGIC MALIGNANCIES
		Moderators: George F. Atweh, MD, Janet Cuttner, MD, Janice L. Gabrilove, MD
		MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS
		New Approaches and New Agents
8:10		MOLECULAR CHARACTERIZATION AND THERAPEUTIC TARGETS IN MPD
		Ronald Hoffman, MD
8:25		JAK2 and MPL MUTATIONS
		Richard T. Silver, MD, FACS, Ayalew Tefferi, MD
8:40		EPIGENETIC THERAPY IN MDS
		Hagop M. Kantarjian, MD
8:55		VORELOXIN (SNS-595): AN ACTIVE AGENT IN AML
		Gail J. Roboz, MD
9:10		THERAPY FOR POST-IMATINIB FAILURES
		Jorge E. Cortes, MD
9:25		APPROACH TO FRONT-LINE THERAPY IN CLL
		Kanti R. Rai, MD
9:40		LENALIDOMIDE AND RITUXIMAB IN CLL
		Asher Chanan-Kahn, MD
9:55		FLAVOPIRODOL IN CLL
		Janice L. Gabrilove, MD
10:10		Coffee Time
10:40		LUMILIXIMAB STUDIES IN CLL
		Susan O'Brien, MD
10:50		UPDATE on IMIDS in NHL
		Myron Czuczman, MD
11:00		TARGETED THERAPY FOR DIFFUSE LARGE B-CELL LYMPHOMAS
		Ari Melnick, MD
11:15		BORTEZOMIB AND LENALIDOMIDE-BASED TRIALS
		David H. Vesole, MD, PhD
11:30		CARFILZOMIB: A NOVEL PROTEASOME INHIBITOR IN MYELOMA AND OTHER MALIGNANCIES
		Howard A. Burris, MD
11:45		Discussion
12pm		LUNCH AND PRESENTATIONS
		NEW DEVELOPMENTS IN MULTIPLE MYELOMA
		Role of Transplantation
		William Bensinger, MD
		Practical Applications of Clinical Trial Data
		Ravi Vij, MD
		AFTERNOON SESSION
1:15		KEYNOTE ADDRESS
		DILEMMAS IN ADJUVANT THERAPY FOR EARLY BREAST CANCER: THE NSABP EXPERIENCE
		Norman Wolmark, MD
		GI CANCERS
		Moderators: Jordan D. Berlin, MD, Howard S. Hochster, MD, Mace L. Rothenberg, MD
1:35		MODIFIED DOCETAXEL-BASED REGIMENS FOR ADVANCED GASTROESOPHAGEAL CANCERS
		Jaffer Ajani, MD
1:50		BIOMARKERS IN DECISION MAKING STAGE II COLON CANCER
		Anthony B. El-Khoueiry, MD
2:00		NEW TYROSINE KINASE INHIBITORS FOR METASTATIC COLORECTAL CANCER
		Paulo M. Hoff, MD, FACP
2:15		CAN CIRCULATING TUMOR CELLS BE A PREDICTIVE MARKER FOR TREATMENT OF COLON CANCER?
		Neal J. Meropol, MD
2:25		SONIC HEDGEHOG: A NEW TARGET IN COLORECTAL CANCER?
		Mace L. Rothenberg, MD
2:40		NEW PARADIGMS IN TREATMENT OF OXALIPLATIN NEUROTOXICITY
		Howard S. Hochster, MD
2:50		REDUCING RISK OF RECURRENT COLON POLYPS
		Eugene W. Gerner, PhD
3:00		Coffee Time
3:30		MELPHALAN IN NON-COLORECTAL METASTASES TO THE LIVER
		James Pingpank, MD
3:40		HEATED INTRAPERITONEAL CHEMOTHERAPY (HIPEC) IN METASTATIC GI MALIGNANCY
		Daniel M. Labow, MD
3:50		PERSPECTIVES ON HIPEC THERAPY
		Elliot Newman, MD
4:00		PANCREATIC CANCER: WHERE ARE WE GOING?
		Jordan D. Berlin, MD
4:15		PHARMACOGENOMICS IN CANCER CLINICAL TRIALS
		Craig C. Lockhart, MD
4:30		SMALL CELL CARCINOMA OF THE GI TRACT
		Heine Hansen, Professor, MD
4:45		Discussion
7 - 9 pm		DINNER AND PRESENTATIONS
		THERAPY OPTIONS FOR RITUXIMAB-REFRACTORY INDOLENT NHL
		John P. Leonard, MD
		BENDAMUSTINE AND OTHER TARGETED AGENTS IN NHL
		Ann S. LaCasce , MD


		THURSDAY, NOVEMBER 6
7:00am		BREAKFAST WITH THE PROFESSORS
		TARGETING VEGF RECEPTORS WITH PAZOPANIB: BIOLOGIC RATIONALE AND EMERGING CLINICAL DATA
		Mark D. Pegram, MD
		LAPATINIB: PREVENTING METASTATIC COLONIZATION OF BC CELLS IN THE BRAIN
		Diane Palmieri, MD, PhD
		MORNING SESSION
		Moderators: Franco M. Muggia, MD, Carmel Cohen, MD
		GYNECOLOGICAL CANCERS
8:00		INTRAPERITONEAL THERAPY FOR OVARIAN CANCER: MISSION ACCOMPLISHED?
		Franco M. Muggia, MD
8:15		CISPLATIN RESISTANT OVARIAN CANCER: OXALIPLATIN OR PACLITAXEL?
		Britta K. Stordal, MD
8:30		VORELOXIN (SNS-595) IN PLATINUM-RESISTANT OVARIAN CANCER
		William P. McGuire, MD
8:45		NOVEL INTRAPERITONEAL STRATEGIES FOR MANAGING PLATINUM RESISTANCE
		Stephen B. Howell, MD
9:00		TRABECTEDIN IN RECURRENT OVARIAN CANCER
		Bradley J. Monk, MD
9:15		NATIONAL AND INTERNATIONAL TRIALS IN OVARIAN CANCER
		William P. McGuire, MD
9:30		HARNESSING THE IMMUNE SYSTEM FOR OVARIAN CANCER THERAPY
		KunIe O. Odunsi, MD, PhD
9:45		EXPLOITING GENETIC DEFECTS WITH POLYMERASE INHIBITORS
		Hilary Calvert, MD
10:00		Discussion
10:15		Coffee Time
		BRAIN
10:45		UPDATE: PHASE II TRIAL OF CEDIRANIB IN RECURRENT GLIOBLASTOMA
		Elizabeth R. Gerstner, MD
		NEUROENDOCRINE
11:00		ATIPRIMOD PHASE II TRIAL FOR NEUROENDOCRINE CANCER
		Max Sung, MD
		SARCOMA
11:15		ORAL DEFOROLIMUS IN METASTATIC SOFT-TISSUE AND BONE SARCOMAS
		George Demetri, MD
11:30		INTRAVENOUS REOLYSIN IN BONE OR SOFT TISSUE SARCOMA METASTIC TO LUNG
		Monica M. Mita, MD
11:45		Discussion
12 Noon		LUNCH AND PRESENTATIONS
		ADVANCES IN HCC THERAPY
		Josep M. Llovet, MD
		OVERVIEW OF ASIAN DATA ON HCC
		Bert O'Neil, MD
		AFTERNOON SESSION
		BREAST CANCER
1:30		EZRA M. GREENSPAN MEMORIAL LECTURE
		INNOVATIVE STRATEGIES FOR DRUG DEVELOPMENT
		Howard A. Burris, MD
		Moderators: Seymour Cohen, MD, Larry Norton, MD, George Raptis, MD
1:50		THE SELF-SEEDING MODEL OF CANCER: CLINICAL IMPLICATIONS
		Larry Norton, MD
2:05		NEW ASSAYS TO DETERMINE HER2 STATUS
		Allen Lipton, MD
2:20		FULVESTRANT: WHAT HAVE WE LEARNED FROM USING HIGHER DOSES?
		Irene Kuter, MD, PhD
2:35		COMBINED ANTI-HER2 THERAPY: TRASTUZUMAB AND LAPATINIB
		Harold Burstein, MD, PhD
2:50		TRASTUZUMAB-DM1, A NOVEL APPROACH TO THE TREATMENT OF HER2+ BREAST CANCER
		Ian E. Krop, MD PhD
3:05		Coffee Time
3:35		LAPULEUCEL-T IN IMMUNOTHERAPY OF BREAST CANCER: CLINICAL TRIAL DATA
		John Park, MD
3:50		HER2 VACCINATION IN HIGH RISK BREAST CANCER
		George E. Peoples, MD, FACS
4:05		PROTEASOME INHIBITOR ENHANCES HORMONAL THERAPY IN BREAST CANCER
		Samuel Waxman, MD
4:20		Discussion
		THYROID
4:35		TREATMENT OF IODINE-RESISTANT ADVANCED THYROID CANCER
		Marcia Brose, MD, PhD
		HEAD AND NECK
4:45		OVERCOMING IMMUNOSUPPRESSION IN HEAD AND NECK CANCER WITH CITOPLURIKIN (IRX-2)
		Jeffrey S. Moyer, MD
4:55		Discussion
7 - 9pm		DINNER AND PRESENTATIONS
		PERSONALIZED MEDICINE: TREATMENT DECISION-MAKING
		Norman Wolmark, MD, Harold Burstein, MD, PhD


		FRIDAY, NOVEMBER 7
7:00am		BREAKFAST WITH THE PROFESSORS
		THE CONTROVERSY: ARE ANTHRACYCLINES NECESSARY FOR EARLY BREAST CANCER?
		Stephen E. Jones, MD
		UPDATE ON CHEMOTHERAPY FOR ADVANCED BREAST CANCER
		Stephen Y. Chan, MD
		MORNING SESSION
		URO-ONCOLOGY
		Moderator: Anna C Ferrari, MD
		PROSTATE
8:00		ENDOTHELIAL A: SURVIVAL AND BONE METASTASES IN HRPC
		Nancy A. Dawson, MD
8:15		VACCINE APPROACHES IN EARLY STAGE PC
		Robert S. DiPaola, MD
8:30		ABIRATERONE ACETATE: AN ANDROGEN WITHDRAWAL RESPONSIVE PHENOTYPE IN CRPC
		Eleni Efstathiou, MD, PhD
		RENAL
8:45		DEVELOPING COMBINATION STRATEGIES WITH HISTONE DEACETYLASE INHIBITORS
		Roberto Pili, MD
8:55		PHARMACODYNAMIC TRIAL OF FLT-PET/CT IMAGING IN SUNITINIB-TREATED RENAL CELL CARCINOMA
		Glenn Liu, MD
9:10		Discussion
		LUNG CANCER
		Moderator: Roman Perez-Soler, MD, Marc Ballas, MD
9:25		ROLE OF MAINTENANCE THERAPY IN ADVANCED NSCLC
		Chandra P. Belani, MD
9:40		EGFR INHIBITORS IN NSCLC AND HOW TO SELECT PATIENTS
		Fred Hirsch, MD, PhD
9:55		EVOLVING ROLE OF SUNITINIB IN NSCLC
		Mark A. Socinski, MD
10:05		Coffee Time
10:20		TALACTOFERRIN IN REFRACTORY NSCLC
		Giuseppe Giaccone, MD, PhD
10:30		PERSONALIZED THERAPY APPROACHES FOR ADVANCED NSCLC
		Roy S. Herbst, MD, PhD
10:45		THIRD LINE THERAPY FOR NSCLC AND BEYOND
		Cory Langer, MD
11:00		PHASE II STUDY OF PICOPLATIN FOR 2ND LINE SCLC
		John R. Eckhardt, MD
11:10		UPDATE ON AMRUBICIN IN SCLC
		Robert M. Jotte, MD, PhD
11:20		PHASE I/II STUDY OF DOCETAXEL PLUS OBATOCLAX (GX17-070) IN RELAPSED NSCLC
		Alberto A. Chiappori, MD
11:30		MAG3 VACCINATION FOR LUNG CANCER
		Nasser Altorki, MD
11:40		LUNG CANCER VACCINE L-BLP25
		Nevin Murray, MD
11:50		Discussion
12 Noon		LUNCH AND PRESENTATIONS
		EVEROLIMUS FOR RENAL CELL CARCINOMA
		Robert J. Motzer, MD
		ASA-404: A NOVEL VASCULAR DISRUPTING AGENT FOR LUNG CANCER THERAPY
		Primo N. Lara Jr., MD
		AFTERNOON SESSION
1:15		JUDAH FOLKMAN MEMORIAL LECTURE
		IMMUNE THERAPY FOR OVARIAN CANCER: ARE WE READY TO LAUNCH?
		George Coukos, MD, PhD
		DIVERSE THERAPEUTICS
		Moderators: Edward Ambinder, MD, Sylvia Adams, MD, Jorge Gallardo, MD
		MELANOMA
1:35		STAGING AND PROGNOSTIC CRITERIA
		Charles Balch, MD
1:50		SYSTEMIC ADH-1 AND MEPHALAN ILI IN ADVANCED EXTREMITY
		Douglas S. Tyler, MD
2:05		THE EVOLUTION OF OBLIMERSEN
		Anna Pavlick, MD
		IMMUNOTHERAPY
2:15		RADIOTHERAPY WITH IMMUNOTHERAPY
		Silvia Formenti, MD
		SOLID TUMORS
2:25		NOVEL ANTICANCER AGENTS IN THE NCI CTEP CLINICAL DEVELOPMENT PROGRAM
		John J. Wright, MD, PhD
2:40		AMG386: A FIRST-IN-CLASS ANGIOPOIETIN TARGETED THERAPY
		Alain C. Mita, MD
2:50		TERAMEPROCOL INFUSION FOR REFRACTORY SOLID TUMORS
		Jeffrey Infante, MD
3:00		Coffee Time
3:15		ENILURACIL: CLINICAL UPDATE ON NOVEL SCHEDULES WITH A DPD-INHIBITOR
		Howard A. Burris, MD
		OTHER CLINICAL OPTIONS
3:25		EVALUATION OF MLN 8237: A NOVEL AURORA A KINASE INHIBITOR
		E. Claire Dees, MD
3:35		RECENT DATA FROM THE Z-FAST AND ZO-FAST TRIALS
		Allan Lipton, MD
3:45		AERODIGESTIVE CANCER PREVENTION
		Alex Adjei, MD
4:00		GENERIC TREATMENT PLAN TEMPLATE
		Joseph Jacobson, MD
4:15		LATE BREAKING DEVELOPMENTS
4:45		Discussion
7 -9pm		DINNER AND PRESENTATIONS
		CHANGING PARADIGMS IN THE THERAPEUTIC APPROACH TO ADVANCED NSCLC
		Mark Socinski, MD
		CETUXIMAB IN NSCLC
		Thomas J. Lynch, MD


		SATURDAY, NOVEMBER 8
		NEW PERSPECTIVES IN ONCOLOGY PRACTICE
7:00am		Registration & Continental Breakfast
8:00		OPENING REMARKS
		Shannon Holloway, MHS, PA-C (Co-Chair) • Andrea Downey, BSN, MA, AOCN (Co-Chair)
8:10		NOVEL THERAPEUTICS FOR MELANOMA
		Anna Pavlick, DO
8:30		WHEN YOUR PATIENT DIES: PERSONAL GRIEF IN THE PROFESSIONAL SETTING
		Nora Rightmer, LCSW
8:50		MYELODYSPLATIC SYNDROME: SUPPORTIVE CARE TO ACTIVE TREATMENT
		Sandra Allen-Bard, BSN, MSN, APN-C, AOCNP
9:10		MAKING THE LAW WORK FOR YOU AND YOUR PATIENT: DOCUMENTING & PRESCRIBING CONTROLLED SUBSTANCES
		Jennifer Bolen, JD
9:35		NEW ADVANCES IN mTor THERAPY
		Andrea Rustine, PA-C
9:55		CHEMOBRAIN & COGNITIVE FUNCTION
		Lynne Wagner, PhD
10:15		BREAK
10:35		KEYNOTE ADDRESS
		DEALING WITH EMOTIONS, STRENGTHENING RELATIONSHIPS
		Robert Buckman, MD
11:05		THE CHANGING PRACTICE MANAGEMENT ENVIRONMENT
		Joseph Bailes, MD
11:25		TRANSPLANT-RELATED INFECTIONS: THE CHALLENGE CONTINUES
		Angela Johns, RN, MPA, ANP
11:45		USE OF METHADONE IN CANCER TREATMENT
		Nessa Coyle, PhD, NP
12:05		LUNCH
1:15		VIDEO: CANCER THROUGH THE EYES OF THE PATIENT AND FAMILY
		Teresa Gilewski, MD
1:40		PATIENT-CENTRIC QUALITY ONCOLOGY CARE
		Edward Ambinder, MD
2:00		EMERGING TRENDS IN MULTIPLE MYELOMA TREATMENT
		Faiza Zafar, PA-C
2:20		PALLIATIVE INTERVENTIONS IN THE ONCOLOGY WORLD
		Christopher Comfort, MD
2:40		ADHERENCE TO THERAPY: IT MAY BE A BIGGER ISSUE THAN YOU REALIZE
		Cathy Maxwell, RN, OCN
3:00		TRENDS IN THE MANAGEMENT OF COLORECTAL CANCER
		Shannon Holloway, MHS, PA-C
3:40		EMERGING TRENDS IN THE MANAGEMENT OF VTE IN CANCER PATIENTS
		Edith Nutescu, PharmD
4:00		CLOSING REMARKS
		Shannon Holloway, MHS, PA-C (Co-Chair) • Andrea Downey, BSN, MA, AOCN (Co-Chair)

Schedule of Sessions

Tuesday, Nov 4, 1:30pm - 5:00pm, Pediatric Oncology
Wednesday, Nov 5, 7:00am - 5:00pm, Hematology & GI Cancers
Thursday, Nov 6, 7:00am - 5:00pm, GYN and Breast Cancers
Friday, Nov 7, 7:00am - 5:00pm, GU, Lung, Melanomas, Brain, Sarcoma, Solid Tumors, Other
Saturday, Nov 8, 7:00am - 4:00pm, Program for Non-Physician Cancer Care Providers

Americans with Disabilities Act: Mount Sinai School of Medicine is in full compliance with provisions of the Americans with Disabilities Act (ADA). If you would like to attend this conference and require any special needs or accommodations, please contact the Page and William Black Post-Graduate School of Medicine at 212-731-7950.